A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: CYP2D6 Polymorphism
Interventions: DRUG: Exemestane Tablets|OTHER: ovarian function suppression/ablation|GENETIC: CYP2D6*10 gene test|DRUG: Tamoxifen
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: Pfizer